Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix


Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Final publication URL
http://www.hta.ac.uk/erg/supplements/supplement1401.pdf#nameddest=article08

Additional data URL
http://www.hta.ac.uk/1859

Indexing Status
Subject indexing assigned by NLM

MeSH
Antimetabolites, Antineoplastic /therapeutic use; Antineoplastic Agents, Phytogenic /therapeutic use; Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Carcinoma /drug therapy /economics /mortality /pathology; Cisplatin /economics /therapeutic use; Cost-Benefit Analysis; Cross-Linking Reagents /therapeutic use; Deoxycytidine /analogs & derivatives /therapeutic use; Disease Progression; Drug Therapy, Combination /economics; Female; Great Britain; Neoplasm Recurrence, Local; Neoplasm Staging; Quality of Life; Quality-Adjusted Life Years; Radiation-Sensitizing Agents /therapeutic use; Topotecan /economics /therapeutic use; Treatment Outcome; Uterine Cervical Neoplasms /drug therapy /economics /mortality /pathology; Vinblastine /analogs & derivatives /therapeutic use

Language Published
English

Country of organisation
England

English summary
An English language summary is available.

Address for correspondence
NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk

AccessionNumber
32013000631

Date abstract record published
19/08/2013